Cargando…

Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo

Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p1...

Descripción completa

Detalles Bibliográficos
Autores principales: Verrier, Bernard, Paul, Stéphane, Terrat, Céline, Bastide, Liza, Ensinas, Agathe, Phelip, Capucine, Chanut, Blandine, Bulens-Grassigny, Laura, Jospin, Fabienne, Guillon, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491952/
https://www.ncbi.nlm.nih.gov/pubmed/28713388
http://dx.doi.org/10.3389/fimmu.2017.00770
_version_ 1783247225367822336
author Verrier, Bernard
Paul, Stéphane
Terrat, Céline
Bastide, Liza
Ensinas, Agathe
Phelip, Capucine
Chanut, Blandine
Bulens-Grassigny, Laura
Jospin, Fabienne
Guillon, Christophe
author_facet Verrier, Bernard
Paul, Stéphane
Terrat, Céline
Bastide, Liza
Ensinas, Agathe
Phelip, Capucine
Chanut, Blandine
Bulens-Grassigny, Laura
Jospin, Fabienne
Guillon, Christophe
author_sort Verrier, Bernard
collection PubMed
description Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p17 and 2F5 in vitro. The p17 sequence was modified to increase sequence identity between the p17 and 2F5 epitopes, which resulted in enhanced cross-reactivity in vitro. Immunogenicity of wild-type and modified p17 was characterized in a rabbit model. Both wild-type and mutated p17 induced anti-gp41 responses in rabbits; sera from these animals reacted with gp41 from different HIV clades. Moreover, introduction of the 2F5 sequence in p17 resulted in induction of antibodies with partially neutralizing activity. Based upon these data, we suggest that the natural cross-reactivity between HIV-1 p17 protein and 2F5 antibody can be exploited to induce antibodies with neutralizing activity in an animal model.
format Online
Article
Text
id pubmed-5491952
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54919522017-07-14 Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo Verrier, Bernard Paul, Stéphane Terrat, Céline Bastide, Liza Ensinas, Agathe Phelip, Capucine Chanut, Blandine Bulens-Grassigny, Laura Jospin, Fabienne Guillon, Christophe Front Immunol Immunology Anti-p17 antibodies are able to neutralize human immunodeficiency virus (HIV) entry in a mouse model. In this study, we identified a region of sequence similarity between the epitopes of anti-p17 neutralizing antibodies and anti-gp41 neutralizing 2F5 antibody and verified cross-reactivity between p17 and 2F5 in vitro. The p17 sequence was modified to increase sequence identity between the p17 and 2F5 epitopes, which resulted in enhanced cross-reactivity in vitro. Immunogenicity of wild-type and modified p17 was characterized in a rabbit model. Both wild-type and mutated p17 induced anti-gp41 responses in rabbits; sera from these animals reacted with gp41 from different HIV clades. Moreover, introduction of the 2F5 sequence in p17 resulted in induction of antibodies with partially neutralizing activity. Based upon these data, we suggest that the natural cross-reactivity between HIV-1 p17 protein and 2F5 antibody can be exploited to induce antibodies with neutralizing activity in an animal model. Frontiers Media S.A. 2017-06-30 /pmc/articles/PMC5491952/ /pubmed/28713388 http://dx.doi.org/10.3389/fimmu.2017.00770 Text en Copyright © 2017 Verrier, Paul, Terrat, Bastide, Ensinas, Phelip, Chanut, Bulens-Grassigny, Jospin and Guillon. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Verrier, Bernard
Paul, Stéphane
Terrat, Céline
Bastide, Liza
Ensinas, Agathe
Phelip, Capucine
Chanut, Blandine
Bulens-Grassigny, Laura
Jospin, Fabienne
Guillon, Christophe
Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
title Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
title_full Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
title_fullStr Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
title_full_unstemmed Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
title_short Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo
title_sort exploiting natural cross-reactivity between human immunodeficiency virus (hiv)-1 p17 protein and anti-gp41 2f5 antibody to induce hiv-1 neutralizing responses in vivo
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491952/
https://www.ncbi.nlm.nih.gov/pubmed/28713388
http://dx.doi.org/10.3389/fimmu.2017.00770
work_keys_str_mv AT verrierbernard exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT paulstephane exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT terratceline exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT bastideliza exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT ensinasagathe exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT phelipcapucine exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT chanutblandine exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT bulensgrassignylaura exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT jospinfabienne exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo
AT guillonchristophe exploitingnaturalcrossreactivitybetweenhumanimmunodeficiencyvirushiv1p17proteinandantigp412f5antibodytoinducehiv1neutralizingresponsesinvivo